A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
for Non-Small Cell Lung Cancer
Drug: Telisotuzumab Vedotin
38 locations incl. Chandler
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT06568939·Phase 2·Recruiting